Clinical Trials Logo
  1. Home
  2. Typhoid Fever
  3. NCT06104345

Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines

Cholera Clinical Trial

Official title:
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines

Clinical Trial Summary

The goal of this clinical trial is to explore the coadministration of oral typhoid fever (Vivotif®) and cholera (Dukoral®) vaccines in healthy volunteers aged 18-65 years. The main question it aims to answer is: • Does coadministration impact the immune responses to Vivotif® and Dukoral® vaccines Participants will: - receive either oral typhoid fever (Vivotif®) or oral cholera (Dukoral®) vaccines or both simultaneously - give blood samples for immunogenicity analyses - participate in adverse event follow up Researchers will compare those receiving only one of the vaccines to those receiving both simultaneously to see if coadministration has an impact on antigen-specific responses measured with: - ELISPOT (plasmablast responses specific to Salmonella typhi, Vibrio Cholerae and Enterotoxigenic Escherichia coli) - ELISA (antibodies in lymphocyte supernatants (ALS) and serum antibodies specific to vaccine antigens)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06104345
Study type Interventional
Source Helsinki University Central Hospital
Contact Anu Kantele, MD, PhD
Phone +358503097640
Email anu.kantele@hus.fi
Status Recruiting
Phase Phase 4
Start date October 2023
Completion date December 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT01895855 - Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Phase 3
Completed NCT01339845 - Introduction of Cholera Vaccine in Bangladesh N/A
Recruiting NCT05829772 - Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence
Completed NCT04760236 - Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™ Phase 3
Recruiting NCT04326478 - Single Dose Azithromycin to Prevent Cholera in Children Phase 2
Completed NCT02928341 - Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo N/A
Completed NCT02864433 - Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts
Recruiting NCT06003816 - Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI) N/A
Not yet recruiting NCT05771779 - Co-administration Study of OCV, TCV and MR Phase 3
Completed NCT04150250 - Cholera Anti-Secretory Treatment Trial Phase 2
Terminated NCT00624975 - Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants Phase 2
Completed NCT00226616 - Zinc Supplementation in Cholera Patients Phase 3
Completed NCT03373669 - Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine Phase 4
Completed NCT02094586 - A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults Phase 3
Completed NCT02100631 - A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults Phase 3
Completed NCT01823939 - PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera Phase 1
Completed NCT01365442 - Pilot Introduction of Oral Cholera Vaccine in Orissa, India N/A
Completed NCT00128011 - Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine Phase 2
Completed NCT00672308 - Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Phase 2
Completed NCT00142272 - Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial Phase 3